Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT07560150 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetics
Pharmacodynamics
Insulin Aspart

Interventions

DRUG: I004
DRUG: NovoLog

Sponsor

Amphastar Pharmaceuticals, Inc.